Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M. González-Martín A, et al. Among authors: de duenas em, de la haba j, de la pena fa. Curr Cancer Drug Targets. 2016;16(5):415-28. doi: 10.2174/1568009615666150817121731. Curr Cancer Drug Targets. 2016. PMID: 26278712 Review.
Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study.
Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, De La Haba J, Tres A, Alvarez I, Alba E, Arcusa A, Oltra A, Batista N, Checa T, Perez-Carrion R, Curto J; GEICAM Group. Pico C, et al. Among authors: de la haba j. Ann Oncol. 2004 Jan;15(1):79-87. doi: 10.1093/annonc/mdh016. Ann Oncol. 2004. PMID: 14679124 Free article. Clinical Trial.
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Barnadas A, Gil M, Sánchez-Rovira P, Llombart A, Adrover E, Estevez LG, de la Haba J, Calvo L. Barnadas A, et al. Among authors: de la haba j. Anticancer Drugs. 2008 Apr;19(4):339-47. doi: 10.1097/CAD.0b013e3282f97f75. Anticancer Drugs. 2008. PMID: 18454044 Review.
A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer.
Bayo-Calero JL, Mayordomo JI, Sánchez-Rovira P, Pérez-Carrión R, Illaramendi JJ, García-Bueno JM, González-Flores E, Crespo C, Ramos-Vázquez M, García-Palomo A, Ruiz-Borrego M, de la Haba J, Gómez-Bernal A, Yubero-Esteban A. Bayo-Calero JL, et al. Among authors: de la haba j. Clin Breast Cancer. 2008 Jun;8(3):264-8. doi: 10.3816/CBC.2008.n.030. Clin Breast Cancer. 2008. PMID: 18650157 Clinical Trial.
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA. Del Barco S, et al. Among authors: de la haba j. Breast Cancer Res Treat. 2009 Jul;116(2):351-8. doi: 10.1007/s10549-008-0218-8. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941891 Clinical Trial.
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.
Puente J, López-Tarruella S, Ruiz A, Lluch A, Pastor M, Alba E, de la Haba J, Ramos M, Cirera L, Antón A, Llombart A, Plazaola A, Fernández-Aramburo A, Sastre J, Díaz-Rubio E, Martin M. Puente J, et al. Among authors: de la haba j. Breast Cancer Res Treat. 2010 Jul;122(2):591-600. doi: 10.1007/s10549-009-0687-4. Epub 2010 Jan 10. Breast Cancer Res Treat. 2010. PMID: 20063196
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo JA, Bermejo B, Carrasco E, Lluch A; GEICAM. Alba E, et al. Among authors: de la haba jr. Ann Oncol. 2012 Dec;23(12):3069-3074. doi: 10.1093/annonc/mds132. Epub 2012 Jun 6. Ann Oncol. 2012. PMID: 22674146 Free article. Clinical Trial.
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sánchez-Rovira P, Ramos M, Rojo F, Burgués O, Carrasco E, Caballero R, Porras I, Tibau A, Cámara MC, Lluch A. Alba E, et al. Among authors: de la haba j. Br J Cancer. 2014 Mar 4;110(5):1139-47. doi: 10.1038/bjc.2013.831. Epub 2014 Jan 23. Br J Cancer. 2014. PMID: 24457911 Free PMC article. Clinical Trial.
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P. Salvador J, et al. Among authors: de villena mc, de la haba j. Clin Transl Oncol. 2015 Feb;17(2):160-6. doi: 10.1007/s12094-014-1210-x. Epub 2014 Aug 14. Clin Transl Oncol. 2015. PMID: 25119930 Clinical Trial.
34 results